An unexpected role for cyclin E-CDK2 in regulating responses to cancer immunotherapy.

Elevated cyclin E-CDK2 activity in cancers suppresses immunotherapy responses by phosphorylating BRD4 and reducing interferon-stimulated gene expression.

• Why it matters: Understanding mechanisms that limit immunotherapy effectiveness is crucial for improving cancer treatments. The role of cell cycle regulators like cyclin E-CDK2 in immune response modulation was previously unclear.
• What they did: Chu et al. analyzed cancer models with increased cyclin E-CDK2 activity and identified its phosphorylation of BRD4 as a key step in downregulating interferon-stimulated genes, using molecular assays.
• The result: Their findings reveal that targeting cyclin E-CDK2 or BRD4 could enhance immunotherapy efficacy, offering new strategies to overcome resistance in cancers with high cyclin E-CDK2 activity.